Mutations in TRAPPC11 are associated with a congenital disorder of glycosylation

Leslie Matalonga,1,2 Miren Bravo,1,2 Carla Serra-Peinado,2 Elisabeth García-Pelegri,1 Olatz Ugartebertu,3 Silvia Vidal,1 Maria Lambrich,1 Ester Quintana,1 Pedro Fuster-Jorge,2 Maria Nieves Gonzalez-Bravo,3 Sergi Beltran,4,5 Joaquín Dopazo,6 Francisco García-García,8 François Foulquier,7 Gert Matthijs,8 Philippa Mills,9 Antonia Ribes,1 Gustavo Egea,1 Paz Briones,1 Frederic Tort,1,7* and Marisa Girós1,7

1 Secció d’Errors Congènits del Metabolisme - IBC, Servei de Bioquímica i Genètica Molecular, Hospital Clinic, IDIBAPS, CIBERER, Barcelona, Spain; 2 Department Biomedicina, Universitat de Barcelona and Institut d’Investigacions Mèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; 3 Neonatologia Hospital Universitario de Canarias, La Laguna, Sta Cruz de Tenerife, Canarias, Spain; 4 CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Baldirí i Reixac 4, Barcelona, Spain; 5 Universitat Pompeu Fabra (UPF), Barcelona, Spain; 6 Centro de Investigación Príncipe Felipe (CIPF, CIBERER), c/Eduardo Primo Yufeta 3, Valencia; 7 Université de Lille/CNRS, UMR 8576 – UGSF – Unité de Glycobiologie Structurale et Fonctionnelle F., Lille, France; 8 Centre for Human Genetics KU Leuven, Leuven, Belgium; 9 Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London, United Kingdom

Communicated by Elizabeth F. Neufeld
Received 24 August 2016; accepted revised manuscript 1 November 2016.
Published online in Wiley Online Library (www.wiley.com/humanmutation). DOI: 10.1002/humu.23145

ABSTRACT: Congenital disorders of glycosylation (CDG) are a heterogeneous and rapidly growing group of diseases caused by abnormal glycosylation of proteins and/or lipids. Mutations in genes involved in the homeostasis of the endoplasmic reticulum (ER), the Golgi apparatus (GA), and the vesicular trafficking from the ER to the ER–Golgi intermediate compartment (ERGIC) have been found to be associated with CDG. Here, we report a patient with defects in both N- and O-glycosylation combined with a delayed vesicular transport in the GA due to mutations in TRAPPC11, a subunit of the TRAPPIII complex. TRAPPIII is implicated in the anterograde transport from the ER to the ERGIC as well as in the vesicle export from the GA. This report expands the spectrum of genetic alterations associated with CDG, providing new insights for the diagnosis and the understanding of the physiopathological mechanisms underlying glycosylation disorders. Hum Mutat 00:1–4, 2016. © 2016 Wiley Periodicals, Inc.

KEY WORDS: CDG; TRAPPC11; Golgi; endoplasmic reticulum; vesicle trafficking

Congenital disorders of glycosylation (CDG) are a heterogeneous and rapidly growing group of diseases caused by abnormal glycosylation of proteins and/or lipids. Human CDG include mutations in genes involved in the homeostasis of the endoplasmic reticulum (ER) and the Golgi apparatus (GA) machinery. CDG patients show a highly heterogeneous clinical phenotype, usually presenting with symptoms during the neonatal period or infancy. The course of the disease is generally severe and the affected individuals show multiorgan involvement including central nervous system, muscle, liver, endocrine system, and coagulation abnormalities [Willett et al., 2013; Freeze et al., 2015]. Although the altered glycoconjugates are diverse, the diagnosis of these individuals relies on the analysis of the glycosylation pattern of serum proteins. Serum transferrin (Tf) is the N-glycoprotein most widely used as a tool to detect N-glycosylation defects. In addition, apoCIII analysis, a mucin-type O-glycoprotein, is also useful to detect O-glycosylation defects. In fact, the aberrant glycosylation patterns of these proteins are reliable biomarkers that point to the potential molecular defects underlying these diseases: defects of N-glycan assembly (CDG-I), N-glycan processing (CDG-II), or combined defects of N- and O-glycosylation.

Mutations in genes involved in the homeostasis of the ER and the GA as well as those implicated in the vesicle trafficking from the ER to the ER–Golgi intermediate compartment (ERGIC) have been found to be associated with CDGs. Indeed, mutations in genes encoding for proteins implicated in vesicular Golgi transport, such as the Conserved Oligomeric Golgi (COG) complex subunits [COG1 (MIM# 606973), COG2 (MIM# 606974), COG3 (MIM# 606975), COG4 (MIM# 606976), COG5 (MIM# 606821), COG6 (MIM# 606977), COG7 (MIM# 606978), and COG8 (MIM# 606979)] were first described as a cause of N-glycosylation type I and O-glycosylation defects [Rosnolet et al., 2013]. In recent years, the implementation of next-generation sequencing technologies has contributed decisively to the description of new CDGs and allowed the identification of new disease-causing mutations in genes encoding for proteins implicated in the homeostasis of the GA [ATP6V0A2 (MIM# 611716), TMEM165 (MIM# 614726), and TMEM199 (MIM# 616815)].

Using whole-exome sequencing, we have identified a CDG patient with a defect in N- and O-glycosylation combined with a delayed ER to Golgi trafficking due to mutations in TRAPPC11 (MIM# 614138), a subunit of the TRAPP III complex.

© 2016 WILEY PERIODICALS, INC.
The patient was a boy from non-consanguineous parents. He was born prematurely at 33 weeks of gestation and weighed 1,550 g. He presented with hypotonia and a malformation syndrome, with microcephaly, retrogastria, camptodactyly, high foot arches (pes cavus), and abnormal facies. MRI showed brain atrophy. Later on, he developed cholestatic liver, recurrent thrombopenia, nephropathy with polyuria, alcalosis, hypernatremia and hypercalcuiuria, and also osteopathy with osteopenia and spontaneous fracture of the tibia. Neurophysiologic studies revealed motor and sensitive peripheral neuropathy and an altered central auditory discrimination. He had recurrent infections, with moderate elevation of lactate. He died at 5 months of age.

Extensive metabolic studies were performed at 4 months of age. Metabolite analysis of plasma and urine included amino acids, organic acids, acyl carnitines, free fatty acids, very long chain fatty acids, polyunsaturated fatty acids, branched chain fatty acids, and sterols. All of them showed normal results. Spleen necropsy showed hyperactivities of some lysosomal enzymes (β-galactosidase, β-hexosaminidase, and β-glucuronidase). However, β-glucurocerbrosidase, galactocerebrosidase, β-hexosaminidase, arylsulfatase, and N-acetyl-α-galactosaminidase activities were normal in cultured fibroblasts.

Isoelectric focusing of serum Tf showed a glycosylation pattern compatible with CDG type II (Fig. 1A). SELDI-TOF-MS analysis of plasma glycans revealed an abnormal percentage of N-glycan structures compared with control values, with low biantennary and high monoantennary types of glycans (Fig. 1A). These results were in agreement with those found through the analysis of serum Tf. Moreover, the apoCIII glycosylation pattern showed a clear increase of the non-sialylated forms (Fig. 1A). These observations suggested a combined defect of both N- and O-glycosylation, pointing to a defect of the GA function. Therefore, alterations in the subunits of the COG complex (COG1-8) were analyzed by Western blot and Sanger sequencing but no alterations were found in any of the COG subunits (data not shown). Consequently, we performed whole-exome sequencing of the patient and his healthy parents (Fig. 1B). Since the biochemical phenotype showed a defect in both N- and O-glycosylation, we filtrated for variants of genes encoding for proteins involved in vesicle transport as well as in ER and GA functions. We used several filtering strategies and when a recessive inheritance pattern was postulated we identified two heterozygous missense mutations in TRAPPC11 (transport protein particle complex 11). These mutations (c.1141C>G and c.3310A>G) were predicted to change proline 381 to alanine (p.Pro381Ala) and threonine 1104 to alanine (p Thr1104 Ala), respectively (Fig. 1B and C) (GenBank accession number NM_021942.5, nucleotide numbering uses +1 as the A of the ATG translation initiation codon in the reference sequence, with the initiation codon as codon 1). The c.1141C>G mutation was not annotated in the Exome Aggregation Consortium (ExAC) database (LDSB database: http://databases.lodw.nl/shared/variants/000132350). Interestingly, the c.3310A>G substitution (rs78663235) has already been reported in the ExAC database with a global allele frequency of 0.0015, but no homozygous individuals for this change have already been reported in the European population. Compound heterozygosity was corroborated by the carrier status of the father (c.[3310A>G]+[ = ]) and the mother (c.[1141C>G]+[ = ]). Results were confirmed by Sanger sequencing. TRAPPC11 encodes for a large protein of 1,33 amino acids with two conserved functional regions: the foie gras and gryzym domains (Fig. 1C). TRAPPC11 has been described to be involved in the assembly and integrity of the TRAPP III complex, which is implicated in the anterograde vesicular membrane transport from the ER to the ERGIC as well as in vesicle mediated export from the Golgi in mammals [Kim et al., 2006; Scrivens et al., 2011; Brunet and Sacher, 2014]. The two missense variants identified in our patient correspond to highly conserved amino acids in higher eukaryotes, one of them within the foie gras domain (Fig. 1C and Supp. Fig. S1). The fact that the TRAPPC11 protein levels in fibroblasts of the patient were similar to those seen in control cells suggest that these mutations do not compromise the stability of the protein but likely its function in the whole complex (Fig. 1D). Moreover, the subcellular localization of TRAPPC11 was not affected by the mutations reported in this patient, since the protein properly localizes in the GA, as expected (Supp. Fig. S2).

Previous studies identified mutations in TRAPPC11 in three families with a clinical phenotype of muscular dystrophy and myopathy with movement disorders and intellectual disability [Bögershausen et al., 2013], in another patient with congenital muscular dystrophy with fatty liver and infantile-onset catacaracts [Liang et al., 2015] and recently in four patients from two unrelated families with triple A syndrome (MIM# 231550) (Koehler et al., 2016). However, none of these patients were identified to be associated with an abnormal Tf or ApoCIII profile, nor with a CDG syndrome. Immunofluorescence studies using antibodies against cis and trans-Golgi markers demonstrated a severe fragmentation of the GA in one of the previous reports [Bögershausen et al., 2013]. Intriguingly, the morphology of the GA was normal in fibroblasts from our patient, as no significant differences were found in the degree of Golgi compaction compared with control cells (Fig. 1A). As TRAPPC11 is known to be involved in ER to Golgi vesicular trafficking, we therefore tested whether this pathway was affected by TRAPPC11 mutations. Thus, cells were treated with brefeldin A (BFA), an inhibitor of the ER–Golgi anterograde transport (Jackson, 2000). On BFA treatment, both patient and control fibroblasts showed the complete disassembly of the GA (Fig. 1A). Interestingly, after the removal of BFA, a significant delay in the reassembly of the GA was observed in patient fibroblasts. These results revealed a defect in the anterograde vesicular transport in the TRAPPC11 patient reported here (Fig. 1A). In addition, the functionality of the retrograde Golgi vesicle transport was also assessed in our patient but no abnormalities were observed (data not shown). These results are in agreement with the vesicular stomatitis virus (VSV-G) trafficking defect observed in the patients reported by Bögershausen et al. (2013).

Previous studies in mammalian cellular models have demonstrated that the presence of TRAPPC11 is critical to keep the integrity of the TRAPP III complex, as its total depletion resulted in strong fragmentation of both, the GA and the ERGIC [Scrivens et al., 2011]. However, in our patient, an alteration in the GA dynamics was only detected on BFA treatment. We hypothesize that the normal expression levels and the correct subcellular localization of the mutant TRAPPC11 protein of our patient may be sufficient to maintain, at least partially, the integrity of the TRAPP III complex and, subsequently, the structure of the GA regardless of the evident ER–Golgi anterograde transport defect (Fig. 1D and Supp. Fig. S2A). However, the question whether the slight TRAPPC11 alteration resulted in such a severe clinical phenotype remains unanswered.

The main biochemical feature of the TRAPPC11 patient reported here is the abnormal N and O-glycosylation pattern detected in plasma Tf and apocIII proteins (Fig. 1A). This finding is novel and provides a reliable biochemical marker for the diagnosis of this disorder. Moreover, our observations are supported by a recently published study using a zebrafish model carrying a mutation in the TRAPPC11 foie gras domain [DeRossi et al., 2016]. In that work, the authors demonstrated that lipid-linked oligosaccharides were decreased in the TRAPPC11 mutant animals and hypothesized that TRAPPC11 deficiency causes a dysfunction in
Figure 1. Identification of TRAPPC11 mutations in a patient with defects in N- and O-glycosylation. A: Analysis of plasma glycans from the TRAPPC11 patient by SELDI-TOF-MS in negative ion mode (left panel) together with transferrin and Apo CIII glycosylation patterns (right panel) of a control individual (C), a CDG type I patient (CDG-I), and the TRAPPC11 patient (P). SELDI-TOF-MS showed an altered percentage of N-glycan structures compared with control values. The major abnormal species corresponds to biantennary N-linked glycan that lacks a single sialic acid (SA) residue and a single galactose (Gal) residue. Relative amounts are presented as a percentage of the total identified N-linked glycan structures compared with control values. n.d., not detectable; SA, sialic acid; Gal, galactose; GlcNac, N-acetylglucosamine. B: Exome data analysis and filtering steps leading to the identification of TRAPPC11 as a putative genetic cause of the disease. C: Human TRAPPC11 protein scheme showing the position of the identified mutations. D: Western blot analysis of TRAPPC11 in patient fibroblasts (P) and in a control individual (C). SDHA was used as loading control.

In summary, this report expands the spectrum of genetic alterations associated with CDG, providing new insights into the diagnosis as well as for the understanding of the physiopathological mechanisms underlying vesicle trafficking defects and glycosylation disorders. We highlight the importance of an accurate biochemical characterization to direct the genetic data analysis when using next-generation sequencing tools. Our study demonstrates that TRAPPC11 deficiency could lead to a disorder targeting the GA function which might be readily identified by routine screening for abnormal glycosylation patterns of plasma proteins.

ACKNOWLEDGMENTS

We thank Dr. Angela Arias (Hospital Clinic de Barcelona) for fibroblasts culturing and Dr. Margarita Rodes (Hospital Clinic de Barcelona) for performing the amino acids analyses. We also thank Dr. Amparo Chabás (Hospital Clinic de Barcelona) for performing the lysosomal enzymatic activities. Library preparation and whole-exome sequencing were performed at the Centro Nacional de Análisis Genómico (CNAG-CRG, Barcelona, Spain). We are grateful to the family involved in this study.

Disclosure statement: The authors declare no conflict of interest.
Figure 2. ER-to-Golgi anterograde membrane flow is defective in the TRAPPC11 patient. A: Fibroblasts from the TRAPPC11 patient and from a control individual were treated with brefaldin A (BFA) for 15 min to block ER-Golgi anterograde transport. B: After BFA removal, the percentage of cells with assembled Golgi apparatus, together with the (C) Golgi compaction index (calculated as $4\pi \times \frac{\text{area}}{\text{perimeter}^2}$) were analyzed at different time points, using the Fiji image processing package (Schindelin et al., 2012). Antibody against GM130 was used to stain the Golgi apparatus. D: Fibroblasts from TRAPPC11 patient and from a control individual were analyzed by qPCR for expression of four UPR (unfolded protein response) effectors and target genes using the comparative Ct method. GAPDH gene was used as an internal control. Results are expressed in relative units (RU), *P < 0.05.

Ethics

All the procedures were approved by the ethics committee of the Hospital Clinic, Barcelona. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (Hospital Clinic de Barcelona) and with the Helsinki Declaration of 1975, as revised in 2000.

References


